Cargando…

Mineralocorticoid Receptor Antagonism in Chronic Kidney Disease

The overactivation of the mineralocorticoid receptor (MR) in animal models of chronic kidney disease (CKD) increases sodium retention and hypertension and provokes inflammation and fibrosis in the kidneys, blood vessels, and the heart; these processes play an important role in the progression of car...

Descripción completa

Detalles Bibliográficos
Autores principales:	Georgianos, Panagiotis I., Agarwal, Rajiv
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418944/ https://www.ncbi.nlm.nih.gov/pubmed/34514191 http://dx.doi.org/10.1016/j.ekir.2021.05.027

Ejemplares similares

Mineralocorticoid Receptor Antagonists—Use in Chronic Kidney Disease
por: Baran, Wiktoria, et al.
Publicado: (2021)

Mineralocorticoid Receptor Antagonism Prevents the Synergistic Effect of Metabolic Challenge and Chronic Kidney Disease on Renal Fibrosis and Inflammation in Mice
por: Palacios-Ramirez, Roberto, et al.
Publicado: (2022)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
por: Vodošek Hojs, Nina, et al.
Publicado: (2021)

Effect of Mineralocorticoid Receptor Antagonism and ACE Inhibition on Angiotensin Profiles in Diabetic Kidney Disease: An Exploratory Study
por: Kovarik, Johannes J., et al.
Publicado: (2021)

Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists
por: Mende, Christian W., et al.
Publicado: (2023)

Does Mineralocorticoid Receptor Antagonism Prevent Calcineurin Inhibitor-Induced Nephrotoxicity?
por: Mortensen, Line Aas, et al.
Publicado: (2017)

Mineralocorticoid receptor-antagonism prevents COVID-19-dependent glycocalyx damage
por: Fels, Benedikt, et al.
Publicado: (2022)

Real-world evidence for steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease
por: Folkerts, Kerstin, et al.
Publicado: (2022)

Mineralocorticoid receptor antagonism in diabetes reduces albuminuria by preserving the glomerular endothelial glycocalyx
por: Crompton, Michael, et al.
Publicado: (2023)

Relative Importance of Aortic Stiffness and Volume as Predictors of Treatment-Induced Improvement in Left Ventricular Mass Index in Dialysis
por: Georgianos, Panagiotis I., et al.
Publicado: (2015)

Prevention of intradialytic hypotensive episodes: is setraline an effective pharmacological approach?
por: Georgianos, Panagiotis I., et al.
Publicado: (2019)

Mineralocorticoid Receptor Antagonists for Preventing Chronic Kidney Disease Progression: Current Evidence and Future Challenges
por: Fujii, Wataru, et al.
Publicado: (2023)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
por: Kawanami, Daiji, et al.
Publicado: (2021)

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
por: Agarwal, Rajiv, et al.
Publicado: (2020)

Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone—Translational Aspects and Clinical Perspectives across Multiple Organ Systems
por: Kolkhof, Peter, et al.
Publicado: (2022)

GLUCOCORTICOID-INDUCED HYPERTENSION AND CARDIAC INJURY: EFFECTS OF MINERALOCORTICOID AND GLUCOCORTICOID RECEPTOR ANTAGONISM
por: HATTORI, TAKUYA, et al.
Publicado: (2013)

Mineralocorticoid receptor antagonism by finerenone is sufficient to improve function in preclinical muscular dystrophy
por: Lowe, Jeovanna, et al.
Publicado: (2020)

Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus
por: Wish, Jay B., et al.
Publicado: (2022)

Effects of Chronic Kidney Disease on Nanomechanics of the Endothelial Glycocalyx Are Mediated by the Mineralocorticoid Receptor
por: Fels, Benedikt, et al.
Publicado: (2022)

Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
por: Kim, Dong-Lim, et al.
Publicado: (2023)

Aldosterone and the mineralocorticoid receptor in renal injury: A potential therapeutic target in feline chronic kidney disease
por: Spencer, Sarah, et al.
Publicado: (2020)

Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2022)

Evaluation of Mineralocorticoid Receptor Antagonism on Changes in NT-proBNP Among Persons With HIV
por: Srinivasa, Suman, et al.
Publicado: (2021)

Efficacy of mineralocorticoid receptor antagonism in the acute myocardial infarction phase: eplerenone versus spironolactone
por: Fraccarollo, Daniela, et al.
Publicado: (2015)

Sex-specific responses to mineralocorticoid receptor antagonism in hypertensive African American males and females
por: Clemmer, John S., et al.
Publicado: (2019)

Therapeutic Advances in Diabetic Kidney Disease
por: Georgianos, Panagiotis I., et al.
Publicado: (2023)

Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease
por: Georgianos, Panagiotis I., et al.
Publicado: (2022)

Mineralocorticoid receptor blockade—a novel approach to fight hyperkalaemia in chronic kidney disease
por: Ritz, Eberhard, et al.
Publicado: (2013)

Mineralocorticoid receptor blockade—a novel approach to fight hyperkalaemia in chronic kidney disease
por: Ritz, E., et al.
Publicado: (2013)

Chronic Antagonism of the Mineralocorticoid Receptor Ameliorates Hypertension and End Organ Damage in a Rodent Model of Salt-Sensitive Hypertension
por: Zhou, Xiaoyan, et al.
Publicado: (2011)

Nonsteroidal Mineralocorticoid Receptor Antagonist Eliciting Cardiorenal Protection Is a New Option for Patients with Chronic Kidney Disease
por: Liu, Wenyu, et al.
Publicado: (2022)

Mineralocorticoid Receptor Antagonism Attenuates Multiple Organ Failure after Renal Ischemia and Reperfusion in Mice
por: Park, Eun Jung, et al.
Publicado: (2023)

Mineralocorticoid Receptor Antagonism Prevents Type 2 Familial Partial Lipodystrophy Brown Adipocyte Dysfunction
por: Schena, Elisa, et al.
Publicado: (2023)

Importance of Micromilieu for Pathophysiologic Mineralocorticoid Receptor Activity—When the Mineralocorticoid Receptor Resides in the Wrong Neighborhood
por: Griesler, Bruno, et al.
Publicado: (2022)

30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
por: Kolkhof, Peter, et al.
Publicado: (2017)

Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
por: Shah, Monarch, et al.
Publicado: (2023)

The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism
por: Eudy, Rena J, et al.
Publicado: (2011)

Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury
por: Luther, James M., et al.
Publicado: (2012)

The Effect of Mineralocorticoid and Glucocorticoid Receptor Antagonism on Autobiographical Memory Recall and Amygdala Response to Implicit Emotional Stimuli
por: Young, Kymberly D., et al.
Publicado: (2016)

Beneficial Effects of Mineralocorticoid Receptor Antagonism on Myocardial Fibrosis in an Experimental Model of the Myxomatous Degeneration of the Mitral Valve
por: Ibarrola, Jaime, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h1qk9g4bjh50mnmb5rb3i57pv3